Sort by

Send to

Choose Destination

Search results

Items: 11


Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.

Reid G, Kao SC, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, Boyer M, van Zandwijk N.

Epigenomics. 2016 May 17. [Epub ahead of print]


Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.

MacDiarmid JA, Langova V, Bailey D, Pattison ST, Pattison SL, Christensen N, Armstrong LR, Brahmbhatt VN, Smolarczyk K, Harrison MT, Costa M, Mugridge NB, Sedliarou I, Grimes NA, Kiss DL, Stillman B, Hann CL, Gallia GL, Graham RM, Brahmbhatt H.

PLoS One. 2016 Apr 6;11(4):e0151832. doi: 10.1371/journal.pone.0151832. eCollection 2016.


A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells.

Solomon BJ, Desai J, Rosenthal M, McArthur GA, Pattison ST, Pattison SL, MacDiarmid J, Brahmbhatt H, Scott AM.

PLoS One. 2015 Dec 11;10(12):e0144559. doi: 10.1371/journal.pone.0144559. eCollection 2015.


MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma.

Glover AR, Zhao JT, Gill AJ, Weiss J, Mugridge N, Kim E, Feeney AL, Ip JC, Reid G, Clarke S, Soon PS, Robinson BG, Brahmbhatt H, MacDiarmid JA, Sidhu SB.

Oncotarget. 2015 Nov 3;6(34):36675-88. doi: 10.18632/oncotarget.5383.


First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.

Whittle JR, Lickliter JD, Gan HK, Scott AM, Simes J, Solomon BJ, MacDiarmid JA, Brahmbhatt H, Rosenthal MA.

J Clin Neurosci. 2015 Dec;22(12):1889-94. doi: 10.1016/j.jocn.2015.06.005. Epub 2015 Aug 13.


miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.

Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJ, Vallely MP, McCaughan BC, Cooper W, Klebe S, Lin RC, Brahmbhatt H, MacDiarmid J, van Zandwijk N, Reid G.

Oncotarget. 2015 Sep 15;6(27):23480-95.


A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma.

Kao SC, Fulham M, Wong K, Cooper W, Brahmbhatt H, MacDiarmid J, Pattison S, Sagong JO, Huynh Y, Leslie F, Pavlakis N, Clarke S, Boyer M, Reid G, van Zandwijk N.

Am J Respir Crit Care Med. 2015 Jun 15;191(12):1467-9. doi: 10.1164/rccm.201503-0461LE. No abstract available.


Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy.

MacDiarmid JA, Brahmbhatt H.

Curr Opin Biotechnol. 2011 Dec;22(6):909-16. doi: 10.1016/j.copbio.2011.04.008. Epub 2011 May 6. Review.


Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug.

MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, Brahmbhatt VN, Phillips L, Pattison ST, Petti C, Stillman B, Graham RM, Brahmbhatt H.

Nat Biotechnol. 2009 Jul;27(7):643-51. doi: 10.1038/nbt.1547. Epub 2009 Jun 28.


Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle inhibitors.

MacDiarmid JA, Madrid-Weiss J, Amaro-Mugridge NB, Phillips L, Brahmbhatt H.

Cell Cycle. 2007 Sep 1;6(17):2099-105. Epub 2007 Jun 27.


Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics.

MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, Haasdyk JE, Dickson KA, Brahmbhatt VN, Pattison ST, James AC, Al Bakri G, Straw RC, Stillman B, Graham RM, Brahmbhatt H.

Cancer Cell. 2007 May;11(5):431-45.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk